25 results
8-K
QNCX
Quince Therapeutics Inc
24 Jul 23
Entry into a Material Definitive Agreement
7:16am
on the Company or EryDel; and (e) retention of certain key employees.
The Company and EryDel are permitted under certain circumstances to terminate
8-K
EX-2.1
QNCX
Quince Therapeutics Inc
24 Jul 23
Entry into a Material Definitive Agreement
7:16am
” means, with respect to any asset, any mortgage, deed of trust, lien, pledge, charge, security interest, title retention device, collateral assignment … substance, intermediates, works-in-process, formulation materials, reference
standards, drug product clinical reserve samples, packaged retention
PRE 14A
joz7k8c
4 Apr 23
Preliminary proxy
4:33pm
8-K
EX-2.1
8b970865e9igc
12 May 22
Entry into a Material Definitive Agreement
5:12pm
8-K
EX-99.1
r6qtzb7qpslclbxxdqr3
10 May 22
Cortexyme Announces Agreement to Acquire Novosteo
8:08am
8-K
EX-10.1
dpuza39uhi79zr eqm
23 Dec 21
Entry into a Material Definitive Agreement
5:26pm
10-K
c95u44
16 Mar 20
Annual report
4:16pm
424B4
a72 axszim0l1p5c
9 May 19
Prospectus supplement with pricing info
5:14pm